瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者PCI治疗后血清炎症因子表达的影响

目的探讨瑞舒伐他汀与阿托伐他汀对行经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗的急性心肌梗死(acute myocardial infarction,AMI)患者手术前、后血清炎性因子超敏C反应蛋白(high-sensitivityC-reactive protein,hs-CRP)、白细胞介素-8(interleukin-8,IL-8)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)浓度的影响。方法80例行PCI治疗的AMI患者术前及术后分别加服瑞舒伐他汀10 mg/d或阿托伐他汀20 mg/d,持续6个月;术前和术后1个月时应用酶联免疫吸附法(ELISA)测定患者血清中Hs-CRP、IL-8、TNF-α浓度。结果治疗后瑞舒伐他汀组血清中hs-CRP、IL-18、TNF-α浓度均显著低于阿托伐他汀组,差异有统计学意义[(2.28±1.06)mg.L-1 vs.(3.58±1.12)mg.L-1,P<0.05;(16.54±4.81)pg.mL-1 vs.(21.92±5.37)pg.mL-1,P<0.05;(101.89±40.52)ng.L-1vs.(248.46±59.14)ng.L-1,P<0.05]。结论瑞舒伐他汀较阿托伐他汀能显著降低行PCI治疗的AMI患者术后血清中Hs-CRP、IL-8、TNF-α的浓度。

Effects of rosuvastatin and atorvastatin on plasma inflammatory factor expressions in patients with AMI after PCI therapy

Objectives To compare the effects of atorvastatin and rosuvastatin on expressions of plasma high-sensitivity C-reactive protein （hs-CRP）, interleukin-8 （IL-8） and tumor necrosis factor-or （TNF-α） in patients with acute myocardial infarction （AMI） after percutaneous coronary intervention （PCI） therapy. Methods Rosuvastatin and atorvastatin were respectively given with a dose of 10 mg/d and 20 mg/d respectively for 6 months in 80 patients with AMI after PCI. Plasma levels of hs-CRP, IL-8 and TNF-α were detected by enzyme linked immunosorbent assay （ELISA） method before and 1 month after PCI. Results Plasma levels of hs-CRP, IL-8 and TNF-α in rosuvastatin group were obviously lower than those in atorvastatin group after treatment [ （2.28±1.06） mg. L-1 vs. （3.58±1.12） mg L-1, P〈0.05 ; （ 16.54±4.81 ） pg-mL-I vs. （21.92±5.37） pg-mL-1, P〈0.05; （101.89±40.52） ng.L-1 vs. （248.46±59.14） ng L-1, P〈0.05]. Conclusions Compared with atorvastatin, rosuvastatin can effectively decrease plasma levels of hs-CRP, IL-8 and TNF-α in patients with AMI after PCI.